PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.
Analyze analyst forecasts for the company and compare them with competitors.
124.50M
No peer data available for comparison.
-24.90M
No peer data available for comparison.
0.56
No peer data available for comparison.
16.74M
No peer data available for comparison.
-24.90M
No peer data available for comparison.
4.61B
No peer data available for comparison.
Analyze DCF forecasts for the company and compare them with competitors.
No Data
No DCF data available for this metric in the selected year.
-50.53%
Worse than SAVA's revenue growth rate of -25.00%.
No Data
No DCF data available for this metric in the selected year.
-20.00%
Worse than SAVA's ebitda margin of 100.00%.
No Data
No DCF data available for this metric in the selected year.
-20.00%
Worse than SAVA's ebit margin of 100.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
100.00%
Better than SAVA's cash as percentage of revenue of 60.00%.
No Data
No DCF data available for this metric in the selected year.
40.00%
Better than SAVA's receivables as percentage of revenue of 80.00%.
No Data
No DCF data available for this metric in the selected year.
40.00%
Better than SAVA's inventories as percentage of revenue of 80.00%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than SAVA's payables as percentage of revenue of 60.00%.
No Data
No DCF data available for this metric in the selected year.
-29.43%
Better than SAVA's capex as percentage of revenue of 0.00%.
4.99%
Better than SAVA's weighted average cost of capital (wacc) of 5.34%.
5.02%
Better than SAVA's cost of equity of 5.34%.
4.08%
Better than SAVA's cost of debt of 4.40%.
-0.23
Worse than SAVA's beta of -0.58.
30.07M
Better than SAVA's diluted shares outstanding of 41.93M.
1.57M
Worse than SAVA's total debt of 0.00.
49.31M
Worse than SAVA's total equity of 101.06M.
50.89M
Worse than SAVA's total capital of 101.06M.
3.09%
Worse than SAVA's debt weighting of 0.00%.
96.91%
Worse than SAVA's equity weighting of 100.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
2.00%
Equal to SAVA's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Worse than SAVA's net debt of -121.14M.
71.33M
Worse than SAVA's equity value of 112.01M.
2.37
Worse than SAVA's equity value per share of 2.67.